Rindopepimut shows impressive mid-stage results for brain cancer The US biotech company Celldex announced that its investigational vaccine for glioblastoma, the most common type of brain cancer, met the main goal of extending survival time for patients without a progression of the disease in ...

European regulators have adopted a new guideline on biosimilar antibody drugs this Friday. The EMEA briefly touched on the guidelines in a relese with title 'Similar Biological Medicinal Products Containing Monoclonal Antibodies'. The guildline will be released for a ...

In yet another new 'first' for stem cell companies, ReNeuron says that it dosed the first patient in a small stroke study, with an elderly patient on the receiving end of a series of stem cell injections in the brain. ...

Bristol-Myers Squibb today announced that the U.S. FDA delayed its verdict on the company’s monoclone antibody melanoma drug ipilimumab by three months. The experimental cancer agent ipilimumab is one of the new generation of therapies that can kill tumor cells through ...

One of  India's top biotech company Biocon has announced that it would make a strategic investment of around 500 million Malaysian ringgit ($161 million) in Malaysian Biotechnology Corporation SdnBhd (BiotechCorp). According to a statement from the company, ...

Only days after the biotech company MacroGenics announced an impressive discovery and development deal for its DART technology with Boehringer Ingelheim, the Rockville, MD-based developer strikes another deal with Pfizer. The research and development deal with enable Pfizer to use MacroGenics' ...

Last Friday, the pharma giant AstraZeneca  said that the Committee for Medicinal Products for Human Use or CHMP in European Union issued a positive opinion on the marketing authorisation application for its nasal spray vaccine Fluenz for ...

The UK pharma giant GlaxoSmithKline has formed a strategic alliance with Fondazione Telethon and Fondazione San Raffaele, one of the biggest biomedical charities in Italy and the country’s largest private research institute, targeting novel treatments for rare genetic disorders. The ...

Botox gets green light for prevent migraines FDA has approved Botox (onabotulinumtoxin A) for the prophylactic treatment of headaches in adults with chronic migraine, characterised by severe headaches on 15 or more days per month, lasting four hours ...

ImmunoGen forming alliance with Novartis to develop cancer treatment The Waltham, MA-based biotech company ImmunoGen has signed a collaboration agreement with Novartis that lets the Swiss drugmaker develop targeted cancer therapy with fewer side effects. The news gave the targeted anticancer ...